News & Events

• January 25, 2023
  

  C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform

  C-Path today announced that the European Medicines Agency (EMA) has issued a letter of support for the Duchenne Regulatory Science Consortium’s (D-RSC) Model-based Clinical Trial Simulation Platform for Duchenne Muscular Dystrophy (DMD).

• December 1, 2022
  

  C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies

  C-Path and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced a data sharing agreement to incorporate rare disease patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).

• November 10, 2022
  

  C-Path and EFACTS Announce Data Sharing Agreement Making RDCA-DAP the Largest Worldwide Database for Friedreich’s Ataxia

  C-Path and EFACTS today announced a data sharing agreement to incorporate patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), solidifying RDCA-DAP as the largest worldwide database for Friedreich’s ataxia.

• November 2, 2022
  

  C-Path and Eisai Data Sharing Collaboration to Include Lennox-Gastaut Syndrome Registry and Clinical Trial Data

  TUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collaboration to significantly promote data sharing and incorporate Lennox-Gastaut Syndrome (LGS) clinical trial data, into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Lennox-Gastaut syndrome is a severe form of epilepsy with seizures occurring......
• October 27, 2022
  

  C-Path Appoints Neuropharmacology Expert as New Vice President – Rare and Orphan Disease Programs

  C-Path today announced the appointment of Collin Hovinga, Pharm.D., MS, FCCP as Vice President for its Rare and Orphan Disease Programs, and lead for both its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) initiative and Critical Path for Rare Neurodegenerative Diseases (CP-RND) public-private partnership. RDCA-DAP focuses on rare disease data sharing and accelerating therapy development. CP-RND focuses on the accelerating the development of therapies for patients living with rare neurodegenerative diseases, including ALS.